Top

International Journal of Clinical Oncology

Published in:

01-12-2018 | Original Article

Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis

Authors: Seiichi Hosaka, Hirohisa Katagiri, Masashi Niwakawa, Hideyuki Harada, Junji Wasa, Hideki Murata, Mitsuru Takahashi

Published in: International Journal of Clinical Oncology | Issue 6/2018

Abstract

Background

Skeletal-related events (SRE) are common in patients with renal cell carcinoma (RCC) that includes bone metastasis. The purpose of this study was to clarify the effectiveness of zoledronate with and without sunitinib, combined with radiotherapy, for the treatment of bone metastasis from RCC.

Methods

We retrospectively analyzed 62 RCC patients with bone metastasis, who had been treated with radiotherapy at our institution. We divided the study cohort into two groups: patients treated with radiotherapy alone (RT; n = 27) and those treated with radiotherapy combined with zoledronate (RT + Z; n = 35). We investigated the overall survival and post-irradiation (PI)-SRE-free rate for each group, as well as the effect of sunitinib in the RT + Z treatment group. In addition, we determined treatment effectiveness by imaging assessments and relative response rates.

Results

There was no significant difference in the survival rates between the RT and RT + Z treatment groups (p = 0.11). However, the PI-SRE-free rate in the RT + Z group was significantly higher than that in the RT group (p = 0.02). The PI-SRE-free rate was significantly higher in patients who were treated with sunitinib after radiotherapy than in those who were treated without sunitinib (p = 0.03). However, there was no significant difference in the relative response rates, as assessed by imaging, in each group.

Conclusion

Radiotherapy combined with zoledronate is an effective treatment for RCC with bone metastasis to prevent PI-SRE. Sunitinib may reduce PI-SRE if used after radiotherapy and combined with zoledronate.

Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884–891CrossRef

Harrington KD (1988) Management of metastatic bone disease. The CV Mosby Company, St. Louis, pp 7–17

Jasmin C, Capanna R, Coia L et al (2005) Textbook of bone metastases. Wiley, New JerseyCrossRef

Zekri J, Ahmed N, Coleman RE et al (2001) The skeletal complications of renal cell carcinoma. Int J Oncol 19:379–382PubMed

Kijima T, Fujii Y, Suyama T et al (2008) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronete. Br J Urol Int 103:620–624CrossRef

Halperin EC, Harisiadis L (1983) The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 51:614–617CrossRef

Mizumoto M, Harada H, Asakura H et al (2009) Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital. Int J Rad Oncol Biol Phys 79:208–213CrossRef

Fuchs B, Trousdale RT, Rock MG (2005) Solitary bone metastasis from renal cell carcinoma. Clin Orthop Relat Res 431:187–192CrossRef

Oudard S, George D, Medioni J et al (2007) Treatment options in renal cell carcinoma; past, present and future. Ann Oncol 18:25–31CrossRef

10.

Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRef

11.

Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal carcinoma treated with sunitinib. Ann Oncol 22:794–800CrossRef

12.

Rosen LS, Gordon D, Kaminski M et al (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: phase III, double-blind, comparative trial. Cancer J 7:377–387PubMed

13.

Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: phase III, double-blind, randomized trial the zoledronic acid lung cancer and the other solid tumors study group. J Clin Oncol 21:3150–3157CrossRef

14.

Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. Br J Urol Int 96:964–969CrossRef

15.

Harada H, Katagiri H, Kamata M et al (2010) Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res 51:131–136CrossRef

16.

Katagiri H, Okada R, Takagi T et al (2014) New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3:1359–1367CrossRef

17.

Yuasa T, Kitsukawa S, Sukegawa G et al (2013) Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer 13:3CrossRef

18.

Chiang CL, Chen YW, Wu MH et al (2016) Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small-cell lung cancer. J Chin Med Assoc 79:248–255CrossRef

19.

Norick AC, Retik AB et al (2002) Renal tumors. In: Campbells urology 8th edn. W. B. Saunders Co., Philaderphia, pp 2685–2703

20.

Escudier B, EiseEn T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318CrossRef

21.

Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Can 48:333–339CrossRef

22.

Żołnierek J, Nurzyński P, Langiewicz P et al (2010) Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 136:371–378CrossRef

23.

Weber KL, Doucet M, Price JE et al (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63:2940–2947PubMed

24.

Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed

25.

Yokomizo A, Koga H, Shinohara N et al (2010) Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan. Int J Urol 17:332–336CrossRef

26.

Plastaras JP, Kim SH, Liu YY et al (2007) Cell cycle-dependent and schedule-dependent antitumour effects of sorafenib combined with radiation. Cancer Res 67:9443–9454CrossRef

27.

Taussky D, Soulières D (2009) Hypofractioned radiotherapy with concomitant sunitinib—is there a radiosensitizing effect? Can J Urol 16:4599–4600PubMed

28.

Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell carcinoma treated with sunitinib. Ann Oncol 22:794–800CrossRef

Title: Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis
Authors: Seiichi Hosaka
Hirohisa Katagiri
Masashi Niwakawa
Hideyuki Harada
Junji Wasa
Hideki Murata
Mitsuru Takahashi
Publication date: 01-12-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1310-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer

Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors

Novel graded prognostic assessment for colorectal cancer patients with brain metastases

Longitudinal changes in the quality of life of oral cancer patients during the perioperative period

Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization

Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival

Keynote webinar | Spotlight on antibody–drug conjugates in cancer